Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

SAVA
Cassava Sciences, Inc.
stock NASDAQ

At Close
Dec 24, 2025 3:58:30 PM EST
2.24USD+1.818%(+0.04)415,621
2.22Bid   2.25Ask   0.03Spread
Pre-market
Dec 24, 2025 9:22:30 AM EST
2.22USD+0.909%(+0.02)5,408
After-hours
Dec 24, 2025 4:49:30 PM EST
2.22USD-0.893%(-0.02)1,900
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsDividendsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 24, 2022
08:50AM EST  B. Riley Securities Maintains Buy on Cassava Sciences, Lowers Price Target to $72   Benzinga
Jan 14, 2022
12:21PM EST  Cassava Sciences Option Alert: Jan 21 $45 Calls Sweep (4) near the Ask: 80 @ $3.7 vs 1518 OI; Ref=$46.28   Benzinga
Dec 29, 2021
12:07PM EST  Cassava Sciences Whale Trades Spotted   Benzinga
Dec 23, 2021
09:02AM EST  Cassava Sciences Highlights Launch Of Clinical Website To Support Phase 3 Studies Of Oral Simufilam In Alzheimer's Disease   Benzinga
09:00AM EST  -- New website (www.Rethink-ALZ.com) is intended to increase visibility and information for potential study participants. -- Rethink-ALZ.com connects patients with nearest participating clinical site. -- Phase 3 efficacy studies now in over 25 clinical sites across the country.   GlobeNewswire Inc
Dec 22, 2021
10:22AM EST  Here's How Much $1000 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today   Benzinga
08:52AM EST  Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Dec. 22, 2021: TSLA, SEAC, SAVA, DCRN, METX   Benzinga
Dec 21, 2021
09:31AM EST  UPDATE: Editor-in-Chief States: 'After Careful Examination of These Original Material, Neuroscience [Journal] Found No Evidence of Manipulation of the Western Blot Data or Other Figures of This Publication.'   Benzinga
09:30AM EST  Cassava Sciences Says Science Journal Finds No Evidence To Support Claims Of Data Manipulation In 2005 Publication   Benzinga
09:30AM EST  -- Editor-in-Chief States: After Careful Examination of These Original Material, Neuroscience [Journal] Found No Evidence of Manipulation of the Western Blot Data or Other Figures of This Publication. -- Clearance Is From A Neutral Party Who Is Expert In The Field   GlobeNewswire Inc
09:25AM EST  Cassava Sciences Shares Halted On Code News Pending   Benzinga
Nov 26, 2021
07:08AM EST  The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET).   RTTNews
Nov 18, 2021
09:18AM EST  Cassava Sciences Initiates Second Phase 3 Study Of Simufilam For Treatment Of Patients With Alzheimer's Disease   Benzinga
09:15AM EST  Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for   GlobeNewswire Inc
Nov 17, 2021
02:39PM EST  Mid-Afternoon Market Update: Dow Falls 200 Points; Rockwell Medical Shares Spike Higher   Benzinga
12:15PM EST  Mid-Day Market Update: StoneCo Drops After Q3 Earnings; EyePoint Pharmaceuticals Shares Surge   Benzinga
11:01AM EST  Shares of Cassava Sciences, Inc. (SAVA) tanked over 23% on Wednesday morning on report that the Securities and Exchange Commission has commenced an investigation of the pharmaceutical company.   RTTNews
09:09AM EST  SEC Is Probing Cassava Sciences   Benzinga
Nov 10, 2021
09:18AM EST  Cassava Sciences Q3 EPS $(0.24) Down From $(0.06) YoY   Benzinga
09:00AM EST  Cassava Sciences Reports Third Quarter 2021 Financial Results   GlobeNewswire Inc
Nov 5, 2021
09:16AM EDT  Mid-Afternoon Market Update: Nasdaq Jumps 150 Points; NeoPhotonics Shares Spike Higher   Benzinga
09:10AM EDT  Why Cassava Sciences Shares Are Rising   Benzinga
Nov 4, 2021
12:38PM EDT  Mid-Day Market Update: Gold Rises 1.7%; Lightspeed Commerce Shares Plunge   Benzinga
11:20AM EDT  'SAVA Nothing disclosed today improves fundamentals or increases likelihood of simufilam's success. It only makes the stock price more volatile, so trade on. Will simufilam work? No, almost certainly not...' -Tweet From STAT's Adam Feuerstein   Benzinga
10:59AM EDT  Mid-Morning Market Update: Markets Mixed; Moderna Lowers Covid-19 Vaccine Sales Outlook   Benzinga
09:49AM EDT  Cassava Sciences Shares To Resume Trade At 10 a.m. EDT   Benzinga
09:31AM EDT  Cassava Sciences Reports Review By Journal Of Neuroscience Shows No Evidence Of Data Manipulation In Technical Paper Foundational To Co.'s Lead Drug Candidate   Benzinga
09:27AM EDT  Cassava Sciences Shares Halted, News Pending   Benzinga
Nov 2, 2021
06:29PM EDT  Top 10 WallStreetBets Trending Stocks For Afternoon Of Tuesday, Nov. 2, 2021   Benzinga
Oct 25, 2021
04:48PM EDT  Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Cassava Sciences, Inc. - SAVA   PR Newswire
Oct 24, 2021
03:09PM EDT  Final Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds   GlobeNewswire Inc
01:00PM EDT  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.   GlobeNewswire Inc
Oct 22, 2021
10:50PM EDT  CASSAVA SCIENCES 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Cassava Sciences, Inc. - SAVA   Business Wire
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Oct 19, 2021
11:05PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
03:46PM EDT  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.   GlobeNewswire Inc
03:29PM EDT  It Turns Out That The World Still Needs Coal: Good News For Our Recent Top Name, Peabody Energy   Benzinga
Oct 18, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
01:41PM EDT  Final Deadline Approaching on October 26, 2021: Kessler Topaz   GlobeNewswire Inc
Oct 16, 2021
01:00AM EDT  (SAVA) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel   PR Newswire
Oct 15, 2021
10:50PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Oct 14, 2021
10:25AM EDT  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.   GlobeNewswire Inc
Oct 13, 2021
10:28PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Oct 12, 2021
10:44PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
11:01AM EDT  Crisis Investing: From COVID, To Energy, To Supply Chain Breakdowns, The Market Has Been Buffeted By Crises Recently. How We've Navigated Them So Fa.   Benzinga
Oct 11, 2021
10:26PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
04:21PM EDT  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Oct 10, 2021
05:40PM EDT  Important Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Cassava   PR Newswire
Oct 9, 2021
12:03PM EDT  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.   GlobeNewswire Inc
Oct 8, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Oct 6, 2021
08:34AM EDT  Cassava Sciences Initiates a Phase 3 Efficacy Trial Of Simufilam For Treatment Of Patients With Alzheimer's Disease   Benzinga
08:30AM EDT  -- First Phase 3 Study is Initiated to Evaluate Safety and Efficacy of Simufilam Over 52 Weeks in 750 Patients with Alzheimers Disease -- A Second Phase 3 Study, Expected to Begin by Year End, Will Evaluate Simufilam Over 78 Weeks In 1,000 Patients with Alzheimers Disease   GlobeNewswire Inc
Oct 5, 2021
11:24PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
10:00AM EDT  SAVA, HYRE & KPLT Class Actions and Deadlines - Bronstein, Gewirtz   GlobeNewswire Inc
09:15AM EDT  Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases   Benzinga
Oct 4, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
09:09AM EDT  SAVA ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors   GlobeNewswire Inc
Oct 3, 2021
05:28PM EDT  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Oct 1, 2021
10:50PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Sep 30, 2021
01:16PM EDT  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.   GlobeNewswire Inc
10:01AM EDT  Cassava Sciences Option Alert: Oct 8 $70 Calls at the Ask: 176 @ $2.3 vs 575 OI; Earnings 11/8 Before Open [est] Ref=$61.05   Benzinga
Sep 29, 2021
09:51PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
08:43PM EDT  Pomerantz Law Firm Announces the Filing of a Class Action Against Cassava   PR Newswire
08:28AM EDT  Cassava Sciences Sponsored Study Titled 'Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease (RETHINK-ALZ)' Posted To ClinicalTrials.Gov; Study Is Recruiting   Benzinga
Sep 28, 2021
10:26PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
11:52AM EDT  Securities Fraud Class Action Lawsuit was filed on Behalf of Investors of Cassava Sciences, Inc.   PR Newswire
07:43AM EDT  '$SAVA Yale was removed as a participating enrollment center for the company's simufilam REFOCUS-ALZ Phase 3 study.' -STAT Reporter   Benzinga
Sep 27, 2021
10:10PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Sep 25, 2021
11:58AM EDT  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.   GlobeNewswire Inc
11:15AM EDT  (SAVA) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel   PR Newswire
Sep 24, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
07:07PM EDT  Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline   GlobeNewswire Inc
03:57PM EDT  Cassava Sciences Option Alert: Oct 1 $75 Calls Sweep (36) near the Ask: 214 @ $1.3 vs 247 OI; Earnings 11/8 Before Open [est] Ref=$62.0   Benzinga
Sep 23, 2021
08:55PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. (Cassava or the Company) (NASDAQ:SAVA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
11:39AM EDT  Watching Shares Of Cassava Sciences; Maxim Group Maintains Buy Rating   Benzinga
Sep 22, 2021
12:23PM EDT  UPDATE: B. Riley On Cassava Sciences Says Believes Co.'s Phase 3 Is Progressing Ahead Of Investor Expectations   Benzinga
10:03AM EDT  Cassava Sciences, Inc. (SAVA) shares are rising on Wednesday morning trade after the company reported positive results for its open-label study with Simufilam in Alzheimer's disease.   RTTNews
09:47AM EDT  Cassava Sciences Option Alert: Fri $68 Calls at the Ask: 400 @ $1.1 vs 86 OI; Earnings 11/8 Before Open [est] Ref=$56.59   Benzinga
09:06AM EDT  Cassava Posts Encouraging Data From Interim Analysis Of   RTTNews
08:46AM EDT  Cassava Reports Top-line Results From Study Evaluating Simufilam In Alzheimer's Disease; Stock Up   RTTNews
08:44AM EDT  Cassava Sciences Announces Top-line Results Of 12-month Interim Analysis From Open-label Study Evaluating Simufilam   RTTNews
08:31AM EDT  Cassava Sciences Announces Top-Line Results Of 12-month Interim Analysis From Open-Label Study Evaluating Simufilam In Alzheimer's Disease; Says Cognition Scores Improved 3.2 Points On ADAS-Cog, Baseline To Month 12   Benzinga
08:30AM EDT  -- Cognition Scores Improved 3.2 Points on ADAS-Cog, Baseline to Month 12 (p<0.001)   GlobeNewswire Inc
Sep 21, 2021
11:14AM EDT  Cassava Sciences Option Alert: Nov 19 $100 Calls at the Ask: 400 @ $3.0 vs 3518 OI; Earnings 11/8 Before Open [est] Ref=$51.19   Benzinga
Sep 20, 2021
10:48PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
09:31AM EDT  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.   GlobeNewswire Inc
Sep 18, 2021
09:33AM EDT  DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces   GlobeNewswire Inc
Sep 17, 2021
12:18PM EDT  Cassava Sciences Option Alert: Jan, 2023 $195 Calls Sweep (10) near the Ask: 50 @ $10.805 vs 257 OI; Earnings 11/8 Before Open [est] Ref=$45.41   Benzinga
Sep 16, 2021
10:36AM EDT  Loss to Contact Firm's Attorneys Now, SAVA Reportedly Shifts Defense Against Claims of Scientific Misconduct   PR Newswire
Sep 15, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
12:45PM EDT  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.   GlobeNewswire Inc
Sep 14, 2021
10:50PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
Sep 13, 2021
10:50PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Sep 12, 2021
08:22AM EDT  Shareholders of Cassava Sciences, Inc. of Deadline in Securities Fraud Class Action Lawsuit   PR Newswire
Sep 11, 2021
01:54PM EDT  A Reply To Dr Biks on $SAVA PTau-181   Benzinga
01:44PM EDT  What Happens When A Biotech Stock Blows Up: How Our Hedged Portfolio Method Limited The Damage With Cassava Sciences   Benzinga
Sep 10, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
06:14PM EDT  CLASS ACTION REMINDER: Kessler Topaz Meltzer & Check, LLP Reminds   GlobeNewswire Inc
Sep 9, 2021
08:06PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. (Cassava or the Company) (NASDAQ:SAVA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
06:41PM EDT  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.   GlobeNewswire Inc
08:15AM EDT  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, announced today that management will present at H.C. Wainwrights 23rd Annual Global Investment Conference, a virtual event that takes place September 13-15, 2021.   GlobeNewswire Inc
Sep 8, 2021
09:18PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Sep 4, 2021
10:15AM EDT  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.   GlobeNewswire Inc
Sep 3, 2021
12:59PM EDT  Cassava Sciences shares were trading higher after the company released a public statement regarding recent allegations.   Benzinga
10:19AM EDT  Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc. - SAVA   PR Newswire
07:31AM EDT  The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself   Benzinga
07:04AM EDT  Cassava Sciences Releases a Public Statement Regarding Recent Allegations   Benzinga
07:00AM EDT  Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimers disease, today released a public statement regarding recent allegations made against the Company.   GlobeNewswire Inc
Sep 2, 2021
05:00PM EDT  Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud   GlobeNewswire Inc
Sep 1, 2021
05:03PM EDT  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has   GlobeNewswire Inc
10:43AM EDT  (SAVA) Investors with Losses to Contact Firm's Attorneys Now, Securities Fraud Class Period Expanded   PR Newswire
Aug 31, 2021
10:31PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. (Cassava or the Company) (NASDAQ:SAVA). Such investors are advised to contact Robert S. Willoughby atnewaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
12:22PM EDT  Cassava Sciences Option Alert: Fri $50 Calls Sweep (3) near the Ask: 60 @ $8.4 vs 355 OI; Ref=$56.52   Benzinga
09:31AM EDT  (SAVA) Investors to Contact Firm's Attorneys Now, Securities Fraud Case Filed   PR Newswire
Aug 30, 2021
08:00PM EDT  CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cassava Sciences and Encourages Investors to Contact the Firm   Business Wire
02:52PM EDT  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.   GlobeNewswire Inc
12:30PM EDT  Cassava Sciences Sponsored Study Titled 'Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease (REFOCUS-ALZ)' Posted To ClinicalTrials.Gov; Study Not Yet Recruiting   Benzinga
05:51AM EDT  The following are some of the stocks making big moves in Monday's pre-market trading (as of 5.36 A.M. EDT).   RTTNews
Aug 29, 2021
09:48AM EDT  The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week   Benzinga
Aug 27, 2021
02:45PM EDT  Mid-Afternoon Market Update: Crude Oil Rises 2%; Navios Maritime Acquisition Shares Climb On Merger News   Benzinga
11:32AM EDT  Cassava Sciences Issues Statement Related To 'Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer's Patients'   Benzinga
11:32AM EDT  Cassava Sciences Releases Statement Regarding Plasma p-tau   GlobeNewswire Inc
10:10AM EDT  Mid-Morning Market Update: Markets Open Higher; Big Lots Reports Downbeat Profit   Benzinga
09:56AM EDT  Cassava Sciences, Inc. (SAVA) shares are trading down on Friday morning, continuing a slide since August 24, after a 'whistleblower submission' to FDA, questioning Cassava's study data on Alzheimer's testing.   RTTNews
09:19AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Friday, Aug. 27, 2021: BABA, ZM, SAVA, SPRT, CHGG   Benzinga
08:22AM EDT  Quanterix In Statement Following Cassava Reports Says 'Quanterix or its employees did not interpret the test results or prepare the data charts presented by Cassava at the Alzheimer's Association International Conference (AAIC) in July 2021 or otherwise.'   Benzinga
Aug 26, 2021
08:00PM EDT  CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences on Behalf of Cassava Sciences Stockholders and Encourages Investors to Contact the Firm   Business Wire
10:30AM EDT  The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) (Cassava).   GlobeNewswire Inc
09:36AM EDT  (SAVA) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations   PR Newswire
Aug 25, 2021
03:46PM EDT  Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.   GlobeNewswire Inc
02:34PM EDT  Mid-Afternoon Market Update: Dow Rises 100 Points; ScanSource Shares Surge Following Q4 Results   Benzinga
02:14PM EDT  Mid-Day Market Update: Gold Down 1%; Locust Walk Acquisition Shares Jump   Benzinga
02:13PM EDT  Mid-Morning Market Update: Markets Edge Higher; Dick's Sporting Goods Beats Q2 Views   Benzinga
01:28PM EDT  Cassava Sciences Option Alert: Fri $100 Calls Sweep (27) near the Ask: 200 @ $2.25 vs 348 OI; Ref=$86.66 1:27 PM Ocean: ty   Benzinga
12:13PM EDT  Mid-Day Market Update: Gold Down 1%; Locust Walk Acquisition Shares Jump   Benzinga
10:23AM EDT  Cassava Sciences Option Alert: Fri $88 Calls Sweep (68) near the Bid: 1025 @ $8.836 vs 2 OI; Ref=$89.395   Benzinga
10:18AM EDT  Mid-Morning Market Update: Markets Edge Higher; Dick's Sporting Goods Beats Q2 Views   Benzinga
09:29AM EDT  B. Riley On Cassava Following Citizen Petition: 'We would be additional buyers of the shares on weakness'; Notes Petition Cited Data 15+ Years Old, In Peer-Reviewed Publications   Benzinga
09:22AM EDT  UPDATE: Jones Trading On Cassava Following Negative Report On Tuesday: Negative Analysis Contained Figures Published 15+ Years Ago, Articles Brought Into Question Were Published In Reputed Journals With Rigorous Peer Review Process   Benzinga
08:41AM EDT  Why Cassava Sciences' Stock Is Getting Hammered Today   Benzinga
08:23AM EDT  Responding to certain claims posted on-line on Tuesday after market hours, Cassava Sciences, Inc. (SAVA) said it is important for stakeholders to separate fact from fiction. The company noted that these claims regarding scientific integrity are false and misleading. Shares of Cassava Sciences were down 26% in pre-market trade on Wednesday.   RTTNews
07:36AM EDT  Cassava Sciences Responds To Allegations; Stock Down   RTTNews
07:30AM EDT  The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug   Benzinga
06:05AM EDT  Cassava Sciences Issues Response To Negative Claims Made Online   Benzinga
06:00AM EDT  Cassava Sciences Responds to Allegations   GlobeNewswire Inc
Aug 24, 2021
10:22AM EDT  Cassava Sciences Granted U.S. Patent Titled 'Cocrystals of naloxone and naltrexone'   Benzinga
08:36AM EDT  Cassava Sciences Agrees With FDA On Special Protocol Assessments For Simufilam Phase 3 Studies For Alzheimer's Disease   RTTNews
08:18AM EDT  Cassava Sciences Announces Agreement With FDA n Special Protocol Assessments For Its Phase 3 Studies Of Simufilam For Treatment Of Alzheimer's Disease   Benzinga
08:15AM EDT  Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimers disease, announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for both of its pivotal Phase 3 studies of oral simufilam for the treatment of patients with Alzheimers disease.   GlobeNewswire Inc
Aug 20, 2021
03:44PM EDT  Cassava Sciences Option Alert: Sep 17 $100 Calls Sweep (13) above Ask!: 200 @ $22.57 vs 2423 OI; Ref=$103.12   Benzinga
Aug 17, 2021
03:05PM EDT  Cassava Sciences Option Alert: Sep 17 $180 Calls at the Ask: 50 @ $6.8 vs 114 OI; Ref=$102.1361   Benzinga
Aug 13, 2021
08:12PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. (Cassava or the Company) (NASDAQ:SAVA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
09:47AM EDT  Cassava Sciences Option Alert: Aug 20 $150 Calls Sweep (61) near the Ask: 206 @ $1.611 vs 5863 OI; Ref=$118.8039   Benzinga
Aug 12, 2021
02:46PM EDT  Mid-Afternoon Market Update: Dow Drops 50 Points; IEC Electronics Shares Spike Higher   Benzinga
Aug 6, 2021
03:13PM EDT  Cassava Sciences Option Alert: Aug 20 $120 Calls Sweep (3) near the Ask: 120 @ $3.5 vs 2287 OI; Ref=$93.31   Benzinga
01:55PM EDT  Cassava Sciences Option Alert: Sep 17 $110 Calls Sweep (25) near the Ask: 311 @ $12.1 vs 1100 OI; Ref=$94.03   Benzinga
12:49PM EDT  Cassava Sciences Option Alert: Aug 20 $95 Calls Sweep (41) near the Ask: 282 @ $9.8 vs 1133 OI; Ref=$94.29   Benzinga
Aug 3, 2021
11:16AM EDT  Cassava Sciences Earlier Reported Q2 EPS $(0.13) Down From $(0.05) YoY   Benzinga
08:30AM EDT  Cassava Sciences Reports Second Quarter 2021 Financial Results   GlobeNewswire Inc
Aug 2, 2021
07:54PM EDT  Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimers disease, will release financial results for the period ending June 30, 2021 on Tuesday, August 3, 2021 before the market opens, followed by a conference call.   GlobeNewswire Inc
11:15AM EDT  A Forgettable Week For Alzheimer's Treatment Stocks: Two Of Our Top Names Come Back To Earth. This Is Why We Hedge.   Benzinga
Jul 30, 2021
10:55AM EDT  Cassava Sciences, Inc. (SAVA) shares are sliding more than 14 percent on Friday morning trade, despite the company saying biomarker data with Simufilam in Alzheimer's disease is positive. There have been reports of a few researchers questioning the results.   RTTNews
10:00AM EDT  H.C. Wainwright On Cassava Sciences Buy Reiteration: In A Pre-Planned Interim Analysis Of Safety And Cognition Data From The First 50 Subjects Who Completed 9 Months Of Simufilam Treatment Had Improvements From Baseline Cognitive Ability   Benzinga
09:51AM EDT  H.C. Wainwright On Cassava Sciences Buy Reiteration: Firm Believes Results With Simufilam Suggest It Has Potential To Modify The Course Of Alzheimer's Disease   Benzinga
09:49AM EDT  H.C. Wainwright Reiterates Buy On Cassava Sciences, Price Target $124   Benzinga
08:53AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Friday, Jul. 30, 2021: SAVA, PINS, ERYP, LTRN, UAA   Benzinga
07:54AM EDT  The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs   Benzinga
07:06AM EDT  'Alzheimer's scientists critique Cassava Sciences' study results overblown, inappropriate, uninterpretable' -Article By STAT News' Adam Feuerstein   Benzinga
Jul 29, 2021
10:26AM EDT  Mid-Morning Market Update: Markets Open Higher; Mastercard Profit Beats Estimates   Benzinga
09:57AM EDT  UPDATE: Cassava Sciences Trial For Simufilam Was For 25 Patients, Biomarkers For Neuroinflammation, sTREM2, YKL-40 Showed 65%, 44% Decrease   Benzinga
09:54AM EDT  Cassava Sciences Press Release Highlights Cognition, Biomarker Data With Simufilam In Alzheimer's Disesase   Benzinga
08:18AM EDT  The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs   Benzinga
Jul 27, 2021
11:13AM EDT  Cassava Sciences Shares Relatively Quiet Following Circulation Of Seeking Alpha Article '5 Reasons Cassava Sciences Could Still Be The Most Undervalued Stock In The Market'   Benzinga
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 26, 2021
08:35AM EDT  Cassava Sciences Highlights Data With SavaDx From A Randomized Controlled Phase 2b Study Of Simufilam   Benzinga
08:30AM EDT  Cassava Sciences Announces Positive Data with SavaDx from a   GlobeNewswire Inc
Jul 25, 2021
10:05AM EDT  The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More   Benzinga
Jul 23, 2021
04:08PM EDT  An Unforgettable Week For Alzheimer's Treatment Stocks: Two Of Our Recent Top Names Spike On News Of Potentially Promising Treatments   Benzinga
04:01PM EDT  Update On A Bear-Proof Portfolio: The Portfolio We Presented Earlier This Week Is Off To A Fast Start   Benzinga
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
Jul 22, 2021
11:34AM EDT  The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO   Benzinga
Jul 21, 2021
08:31AM EDT  Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer's Association International Conference Jul. 26   Benzinga
08:30AM EDT  - On Monday, July 26th, New Clinical Data for SavaDx to be Shared ina Poster Presentation -   GlobeNewswire Inc
Jul 20, 2021
04:58PM EDT  Building A Bear-Proof Portfolio: Investing Safely Up As The Fear & Greed Index Approaches Early 2020 Levels.   Benzinga
10:27AM EDT  Cassava Sciences shares were trading higher after HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $97 to $124.   Benzinga
07:48AM EDT  10 Biggest Price Target Changes For Tuesday   Benzinga
06:24AM EDT  HC Wainwright & Co. Maintains Buy on Cassava Sciences, Raises Price Target to $124   Benzinga
Jul 1, 2021
10:23AM EDT  Cassava Sciences Option Alert: Jul 16 $90 Calls Sweep (3) near the Ask: 207 @ $9.0 vs 4315 OI; Earnings 8/11 Before Open [est] Ref=$89.44   Benzinga
Jun 23, 2021
09:49AM EDT  B. Riley Securities Maintains Buy on Cassava Sciences, Raises Price Target to $111   Benzinga
04:44AM EDT  44 Biggest Movers From Yesterday   Benzinga
Jun 22, 2021
08:12AM EDT  The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal   Benzinga
Jun 21, 2021
04:12PM EDT  Cassava Sciences Says Selects Premier Research International For Phase 3 Clinical Program In Alzheimer's Disease   Benzinga
04:10PM EDT  Cassava Sciences Selects Clinical Research Organization for Phase   GlobeNewswire Inc
11:45AM EDT  Cassava Sciences Stock Gains After Outlining Clinical Development Progress For Lead Alzheimer's Candidate   Benzinga
08:34AM EDT  Cassava Sciences Offers Mid-Year Update On Clinical Progress   Benzinga
08:30AM EDT  Cassava Sciences Provides Mid-Year Corporate Update, Clinical   GlobeNewswire Inc
Jun 17, 2021
04:01PM EDT  Cassava Sciences To Present At Raymond James 2021 Human Health Innovation Conference Jun. 22   Benzinga
04:01PM EDT  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference, a virtual event taking place on June 21-23, 2021.   GlobeNewswire Inc
01:32PM EDT  Cassava Sciences Option Alert: Jul 16 $90 Calls at the Ask: 1150 @ $8.8 vs 1913 OI; Earnings 8/11 Before Open [est] Ref=$78.75   Benzinga
Jun 14, 2021
08:36AM EDT  Cassava Sciences Names Richard Barry To Board, Effective June 11   RTTNews
08:30AM EDT  - Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals   GlobeNewswire Inc
May 24, 2021
08:30AM EDT  - Virtual Panel to be Held on Wednesday, May 26th, 11:00am Eastern Time -   GlobeNewswire Inc
May 12, 2021
02:15PM EDT  Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development   Benzinga
07:31AM EDT  Cassava Sciences Announces New $2.7M Grant Award From NIH   Benzinga
07:30AM EDT  Cassava Sciences Announces New $2.7 Million Research Grant Award   GlobeNewswire Inc
May 10, 2021
08:30AM EDT  - Randomized, Controlled Study is Designed to Evaluate Cognitionin Patients Who Continue Versus Discontinue Simufilam Over Six Months   GlobeNewswire Inc
Apr 27, 2021
12:06PM EDT  Cassava Sciences Shares Up 4.5%; Maxim Group Issues Note Titled 'Aducanumab PDUFA in June, AAIC In July AD Space Looks Busy Ahead and Simufilam Should be in the Discussion'   Benzinga
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 27, 2021   Benzinga
08:30AM EDT  Cassava Sciences Invited to Participate in B. Riley   GlobeNewswire Inc
06:12AM EDT  B. Riley FBR Initiates Coverage On Cassava Sciences with Buy Rating, Announces Price Target of $78   Benzinga
Apr 26, 2021
08:30AM EDT  Cassava Sciences Invited by the NIH to Participate in Sachs 4th   GlobeNewswire Inc
Apr 21, 2021
02:53PM EDT  Mid-Afternoon Market Update: Dow Jumps 250 Points; Netflix Shares Slide   Benzinga
12:20PM EDT  Mid-Day Market Update: Welbilt Surges Following Acquisition News; Unique Fabricating Shares Plummet   Benzinga
08:37AM EDT  Cassava Sciences Q1 EPS $(0.09) Down From $(0.05) YoY   Benzinga
08:37AM EDT  - 9 Month Interim Analysis of Open-label Study to be Presented ata Major Scientific Conference in July 2021 as an Oral Presentation -   GlobeNewswire Inc
Apr 1, 2021
10:54AM EDT  Cassava Sciences Granted U.S. Patent Application Titled 'METHOD OF INHIBITING TAU PHOSPHORYLATION'   Benzinga
Mar 23, 2021
08:39AM EDT  Cassava Sciences Says Plans To Initiate A Randomized, Placebo-Controlled Cognition Maintenance Study In Alzheimer's Disease   Benzinga
08:32AM EDT  Cassava Sciences Q4 EPS $(0.09) vs $(0.08) In Same Qtr. Last Year   Benzinga
08:30AM EDT  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced financial results for the year ended December 31, 2020 and provided business updates. Unaudited cash and cash equivalents were approximately $280 million as of February 2021.   GlobeNewswire Inc
Mar 17, 2021
10:40AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2021   Benzinga
09:30AM EDT  JonesTrading Initiates Coverage On Cassava Sciences with Buy Rating, Announces Price Target of $110   Benzinga
Mar 9, 2021
09:44AM EST  Shares of Cassava Sciences, Inc. (SAVA) are gaining over 10% on Tuesday morning after the company announced it entered into a drug supply agreement with Evonik Industries AG for simufilam.   RTTNews
09:18AM EST  Cassava Sciences Enters Drug Supply Agreement With Evonik Industries; Evonik To Supply Cassava With Simufilam, A Drug Candidate For Alzheimer's. NOTE: Financial Terms Not Disclosed   Benzinga
Mar 8, 2021
08:47AM EST  Cassava Sciences to Present at the H.C. Wainwright Global Life   GlobeNewswire Inc
Feb 23, 2021
08:30AM EST  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimers disease, has been invited to present at the 10th Annual SVB Leerink Global Healthcare Conference.   GlobeNewswire Inc
07:03AM EST  HC Wainwright & Co. Maintains Buy on Cassava Sciences, Raises Price Target to $97   Benzinga
Feb 22, 2021
12:19PM EST  Cassava Sciences To Start Two Pivotal Trials With Simufilam In Alzheimer's   Benzinga
08:43AM EST  Cassava Sciences Announces Completion Of An End-of-Phase 2 Meeting With FDA For Simufilam   RTTNews
08:32AM EST  Cassava Sciences Reports End-Of-Phase 2 Meeting Results With FDA For Its Alzheimer's Disease Candidate; Deal Reached To Use ADAS-Cog As Co-Primary Efficacy Endpoint; Phase 3 Program Remains On Track To Begin In H2'21   Benzinga
08:30AM EST  - Two Upcoming Phase 3 Studies and a Previously Completed Phase 2 ProgramSupport a New Drug Application Filing for Simufilam in Alzheimers disease -   GlobeNewswire Inc
Feb 16, 2021
10:59AM EST  Maxim Group Maintains Buy on Cassava Sciences, Raises Price Target to $80   Benzinga
06:16AM EST  HC Wainwright & Co. Maintains Buy on Cassava Sciences, Raises Price Target to $66   Benzinga
Feb 12, 2021
05:08PM EST  Cassava Sciences, Inc. (Nasdaq: SAVA) (the Company or Cassava Sciences), a clinical-stage biotechnology company focused on Alzheimers disease, today announced the closing of its previously announced registered direct offering of 4,081,633 shares of its common stock, at a purchase price per share of$49.00, for gross proceeds of approximately$200.0 million.   GlobeNewswire Inc
Feb 11, 2021
12:04PM EST  'Interesting $SAVA nugget: Renaissance Technologies and Hudson Bay CM both filed 13-Gs disclosing zero shares owned...Strange, bc there are no prior filings...' -Tweet From STAT News' Adam Feuerstein   Benzinga
Feb 10, 2021
07:51AM EST  Cassava Sciences Seeks $200M From Equity Offering At 15% Discount To Fund Development Of Lead Candidate   Benzinga
07:34AM EST  The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs   Benzinga
06:20AM EST  New Frontier Health Corporation Shares +$1.23 Premarket; Co Announced Receipt of Preliminary Non-Binding "Going Private" Proposal at $12/Share in Cash   Benzinga
06:16AM EST  Cassava Sciences Announces $200M Registered Direct Offering Of Common Stock   Benzinga
06:15AM EST  Cassava Sciences Announces $200 Million Registered Direct Offering   GlobeNewswire Inc
06:10AM EST  Cassava Science Files for Mixed Shelf; Size Not Disclosed   Benzinga
Feb 8, 2021
08:36AM EST  Cassava Sciences Provides Program Progress And Announces Expected Milestones In 2021   Benzinga
08:30AM EST  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimers disease, today announced significant program progress and expected milestones for 2021.   GlobeNewswire Inc
Feb 5, 2021
07:44AM EST  The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street   Benzinga
Feb 4, 2021
08:26AM EST  Benzinga Pro's Top 5 Stocks To Watch For Thursday, Feb. 4, 2021: API, VGAC, SAVA, AACG, EVBG   Benzinga
07:22AM EST  The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs   Benzinga
Feb 3, 2021
07:31AM EST  The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision   Benzinga
Feb 2, 2021
02:54PM EST  Mid-Afternoon Market Update: Dow Jumps 580 Points; Cassava Sciences Shares Spike Higher   Benzinga
12:31PM EST  Mid-Day Market Update: Crude Oil Rises 3%; Immunovant Shares Plummet   Benzinga
11:11AM EST  Mid-Morning Market Update: Markets Open Higher; Pfizer Reports Mixed Q4 Results   Benzinga
10:27AM EST  Shares of Cassava Sciences, Inc. (SAVA) are surging more than 55% Tuesday morning after the company reported positive data from the study of its lead drug candidate, simufilam for the treatment of Alzheimer's disease.   RTTNews


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC